Clinical trials: Secondary or Primary Immunodeficiency
- Condition Secondary or Primary Immunodeficiency
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
Non-Interventional Study on the Tolerability and Efficacy of IVIG
Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%
- Trial name
- GAM 10-06 (NCT02303093)
- Testing
- Octagam IVIG 5% or 10%, Panzyga
- Where
- 38 sites in Austria, Canada and 3 more
- Volunteers
- 344 people
- Sponsor
- Octapharma